New research explores the unique effects of ADHD medications on Drosophila brain cells

The effect of two drugs used for the treatment of attention-deficit/hyperactivity disorder.

Termination of Agreement for Rifamycin SV MMX® with Dr. Falk Pharma – Biotech Investments

Cosmo Pharmaceuticals N.V. / Key word(s): Agreement Termination of Agreement for Rifamycin SV MMX® with Dr. Falk Pharma 04.09.2023 / 05:45 GMT/BST Dublin, Ireland –

September 5, 2023

Cybin Announces Renewed At-The-Market Equity Program of up to US$35 Million | Psychedelic Invest

Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment

August 24, 2023

Universal genetic testing may improve risk stratification and treatment for rare and lethal cancer

Esophageal adenocarcinoma (EAC) is a highly lethal cancer, with a five-year survival rate of less than 20 percent. Although a precursor lesion to EAC, called

July 27, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.